Taking a Closer Look At Milestone Pharmaceuticals Inc. (MIST) Following Its Recent Trade

0
1

Milestone Pharmaceuticals Inc.’s recent filing unveils that its Director Liebert Debra K. acquired Company’s shares for reported $21040.0 on Oct 21. In the deal valued at $5.26 per share,4,000 shares were bought. As a result of this transaction, Liebert Debra K. now holds 4,000 shares worth roughly $ 19000.0.


China Can't Stop US$0.25 Stock from Mining Ultra-Rare Metal

Here's one little-known company — trading undiscovered below 25-cents per share — that's advancing one of the largest and highest quality REE deposits in all of North America... and the Chinese can't do a damn thing about it! It's early stage... and that's excellent news for individual investors like you who have the foresight to act decisively on an emerging megatrend that's already being measured in the Tens of $Billions.

Simply click here and the name & trading symbol are yours.

Sponsored


Then, Liebert Debra K. bought 10,000 shares, generating $52,900 in total proceeds. Upon buying the shares at $5.29, the Director now owns 10,000 shares.

Before that, Pasternak Richard C bought 10,000 shares. Milestone Pharmaceuticals Inc. shares valued at $52,000 were divested by the Director at a price of $5.20 per share. As a result of the transaction, Pasternak Richard C now holds 10,000 shares, worth roughly $47500.0.

Piper Sandler upgraded its Milestone Pharmaceuticals Inc. [MIST] rating to an Overweight from a a Neutral in a research note published on Friday, April 22, 2022; the price target was increased to $10 from $8. PT values the company’s stock at a premium of 52.5 to its Friday closing price. A number of analysts have revised their coverage, including H.C. Wainwright’s analysts, who began to cover the stock in early March with a ‘”a Buy”‘ rating. Oppenheimer also remained covering MIST and has increased its forecast on July 29, 2020 with a “an Outperform” recommendation from previously “Perform” rating. Jefferies revised its rating on July 24, 2020. It rated MIST as “a Buy” which previously was an “a Hold”.

Price Performance Review of MIST

On Friday, Milestone Pharmaceuticals Inc. [NASDAQ:MIST] saw its stock fall -7.59% to $4.75. On the same session, the stock had its day’s lowest price of $4.65, but rose to a high of $5.13. Over the last five days, the stock has lost -6.68%. Milestone Pharmaceuticals Inc. shares have fallen nearly -27.48% since the year began. Nevertheless, the stocks have fallen -16.52% over the past one year. While a 52-week high of $9.85 was reached on 09/20/22, a 52-week low of $3.98 was recorded on 03/07/22. SMA at 50 days reached $7.72, while 200 days put it at $6.62. A total of 1.03 million shares were traded, compared to the trading of 0.61 million shares in the previous session.

Levels Of Support And Resistance For MIST Stock

The 24-hour chart illustrates a support level at 4.56, which if violated will result in even more drops to 4.36. On the upside, there is a resistance level at 5.04. A further resistance level may holdings at 5.32. The Relative Strength Index (RSI) on the 14-day chart is 29.73, which indicates oversold technical sentiment, while the Moving Average Convergence Divergence (MACD) stands at -0.18, which suggests price will go down in the next trading period. Percent R suggests that price movement has been bearish at 95.59%. Stochastics %K at 6.43% indicates the stock is a buying.

How much short interest is there in Milestone Pharmaceuticals Inc.?

A steep rise in short interest was recorded in Milestone Pharmaceuticals Inc. stocks on Jul 14, 2022, dropping by -1.53 million shares to a total of 0.33 million shares. Yahoo Finance data shows the prior-month short interest on Jun 14, 2022 was 1.86 million shares. There was a decline of -470.22%, which implies that there is a negative sentiment for the stock. In spite of short shares comprising just 1.29% of the overall stock float, the days-to-cover ratio (short ratio) fell to 10.5.

Milestone Pharmaceuticals Inc. [MIST] – Who Are The Largest Shareholders?

In filings from RTW Investments LP, it is revealed that the company now owns 4,315,102 shares, or roughly 14.38% of the outstanding MIST shares. Over the last quarter, Ikarian Capital LLC sold -549,330 shares of Milestone Pharmaceuticals Inc., while Morgan Stanley & Co. LLC sold 499,633 shares. At present, Pura Vida Investments LLC is holding 987,411 shares valued at $9.07 million. Lion Point Capital LP owned 948,570 shares of the company at the time of its most recent 13F filing, worth $8.72 million.

According to FactSet, Milestone Pharmaceuticals Inc.’s share price will average $15.40 in the next year, based on opinions of analysts polled by the firm. This is up nearly 211.28 percent from its previous closing price of $5.14. Analysts expect Milestone Pharmaceuticals Inc. stock to reach the higher price of $20.00, while the lowest price estimate is $10.00. However, 5 analysts have rated MIST stock as a Buy in their predictions for 2022.

LEAVE A REPLY

Please enter your comment!
Please enter your name here